Company Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma.
The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies.
Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Apr 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Dr. Daniel J. Hicklin Ph.D. |
Contact Details
Address: 1030 Massachusetts Avenue Cambridge, Massachusetts United States | |
| Website | https://werewolftx.com |
Stock Details
| Ticker Symbol | HOWL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001785530 |
| CUSIP Number | 95075A107 |
| ISIN Number | US95075A1079 |
| Employer ID | 82-3523180 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Daniel J. Hicklin Ph.D. | Founder, Chief Executive Officer, President, Secretary & Director |
| Dr. Chulani Karunatilake Ph.D. | Chief Technology Officer |
| Timothy W. Trost CPA | Chief Financial Officer, Treasurer & Assistant Secretary |
| Dr. Randi Isaacs M.D. | Chief Medical Officer |
| Dr. William Winston Ph.D. | Senior Vice President of Research |
| Ellen A. Lubman M.B.A. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Aug 08, 2024 | S-8 POS | Filing |
| Aug 08, 2024 | 10-Q | Quarterly Report |
| Aug 08, 2024 | 8-K | Current Report |